Literature DB >> 26008618

Hepatitis C Infection in the Elderly.

Sammy Saab1,2, Justin Rheem3, Vinay Sundaram4.   

Abstract

Hepatitis C virus (HCV) infection in the elderly population is a global medical burden and healthcare utilization concern. The majority of patients with hepatitis C in the USA are "baby boomers," who were born between 1945 and 1965. Consistently worldwide, HCV infection in elderly population is overrepresented and poses public health concerns. These individuals have been infected now for over two decades and are presenting with advanced liver disease. Traditionally, the use of pegylated interferon-based therapy has been limited in the elderly because of its adverse effects. The sustained virologic responses have also tended to be lower in the elderly than in younger adults. The emergence of non-interferon-based therapy with direct acting antiviral agents has expanded the pool of patients eligible for treatment. These agents have been found to be effective, tolerable, and safe in the elderly population.

Entities:  

Keywords:  Antiviral therapy; Elderly; Hepatitis C; Systematic review

Mesh:

Substances:

Year:  2015        PMID: 26008618     DOI: 10.1007/s10620-015-3717-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  84 in total

1.  Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.

Authors:  Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Masahide Oshita; Hideki Hagiwara; Eiji Mita; Toshifumi Ito; Hiroyuki Fukui; Yoshiaki Inui; Taizo Hijioka; Masami Inada; Kazuhiro Kaytayama; Shinji Tamura; Harumasa Yoshihara; Atsuo Inoue; Yasuharu Imai; Michio Kato; Takuya Miyagi; Yuichi Yoshida; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Tetsuo Takehara; Norio Hayashi
Journal:  J Hepatol       Date:  2010-12-09       Impact factor: 25.083

2.  Hepatitis C virus infection in a resident elderly population: a 10-year follow-up study.

Authors:  F Monica; F Lirussi; I Pregun; F Vasile; L Fabris; L Okolicsanyi
Journal:  Dig Liver Dis       Date:  2006-04-14       Impact factor: 4.088

3.  Lipofuscin in bovine muscle and brain: a model for studying age pigment.

Authors:  R D Jolly; B V Douglas; P M Davey; J E Roiri
Journal:  Gerontology       Date:  1995       Impact factor: 5.140

4.  Distribution of hepatitis C virus genotypes in a diverse US integrated health care population.

Authors:  M Michele Manos; Valentina A Shvachko; Rosemary C Murphy; Jean Marie Arduino; Norah J Shire
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

5.  The influence of donor age on liver regeneration and hepatic progenitor cell populations.

Authors:  Yoshihiro Ono; Shigeyuki Kawachi; Tetsu Hayashida; Masatoshi Wakui; Minoru Tanabe; Osamu Itano; Hideaki Obara; Masahiro Shinoda; Taizo Hibi; Go Oshima; Noriyuki Tani; Kisyo Mihara; Yuko Kitagawa
Journal:  Surgery       Date:  2011-06-30       Impact factor: 3.982

6.  Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.

Authors:  C G Nudo; P Wong; N Hilzenrat; M Deschênes
Journal:  Can J Gastroenterol       Date:  2006-09       Impact factor: 3.522

7.  Quality of care in patients with chronic hepatitis C virus infection: a cohort study.

Authors:  Fasiha Kanwal; Mark S Schnitzler; Bruce R Bacon; Tuyen Hoang; Paula M Buchanan; Steven M Asch
Journal:  Ann Intern Med       Date:  2010-08-17       Impact factor: 25.391

8.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors:  Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

9.  Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

Authors:  Chung-Feng Huang; Jeng-Fu Yang; Chia-Yen Dai; Jee-Fu Huang; Nai-Jen Hou; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wen-Yu Chang; Wan-Long Chuang; Ming-Lung Yu
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

10.  Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea.

Authors:  Hyeong Il Kim; In Hee Kim; Byung Jun Jeon; Seok Lee; Seong Hun Kim; Sang Wook Kim; Seung Ok Lee; Soo Teik Lee; Dae Ghon Kim
Journal:  Hepat Mon       Date:  2012-07-30       Impact factor: 0.660

View more
  11 in total

1.  Changing trends in complications of chronic hepatitis C.

Authors:  Mei Lu; Jia Li; Loralee B Rupp; Yueren Zhou; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Sheri Trudeau; Stuart C Gordon
Journal:  Liver Int       Date:  2017-07-21       Impact factor: 5.828

2.  Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.

Authors:  Sabela Lens; Inmaculada Fernández; Sergio Rodríguez-Tajes; Vanessa Hontangas; Mercedes Vergara; Montserrat Forné; Jose Luis Calleja; Moisés Diago; Jordi Llaneras; Susana Llerena; Xavier Torras; Begoña Sacristán; Merce Roget; Conrado Manuel Fernández-Rodríguez; Mari Carmen Navascués; Javier Fuentes; Juan-José Sánchez-Ruano; Miguel-Ángel Simón; Federico Sáez-Royuela; Carmen Baliellas; Rosa Morillas; Xavier Forns
Journal:  Am J Gastroenterol       Date:  2017-06-06       Impact factor: 10.864

3.  Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients.

Authors:  Duminda Suraweera; Vinay Sundaram; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-01

4.  Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1.

Authors:  Yoshinori Ozono; Kenji Nagata; Satoru Hasuike; Hisayoshi Iwakiri; Kenichi Nakamura; Mai Tsuchimochi; Yuri Yamada; Yuka Takaishi; Mitsue Sueta; Tadashi Miike; Yoshihiro Tahara; Shojiro Yamamoto; Kotaro Shide; Tomonori Hidaka; Yoko Kubuki; Kazunori Kusumoto; Toshimasa Ochiai; Junya Kato; Naoto Komada; Shuichi Hirono; Kazuo Kuroki; Masafumi Shigehira; Kazuya Shimoda
Journal:  World J Hepatol       Date:  2017-12-28

5.  Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.

Authors:  Seung Ho Lee; Young-Joo Jin; Jun Young Shin; Jin-Woo Lee
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.

Authors:  Atsushi Naganuma; Kazuaki Chayama; Kazuo Notsumata; Edward Gane; Graham R Foster; David Wyles; Paul Kwo; Eric Crown; Abhi Bhagat; Federico J Mensa; Tetsuya Otani; Lois Larsen; Margaret Burroughs; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2019-03-13       Impact factor: 7.527

Review 7.  Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination.

Authors:  Cristina Stasi; Caterina Silvestri; Fabio Voller
Journal:  SN Compr Clin Med       Date:  2020-10-18

Review 8.  Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.

Authors:  Duminda Suraweera; Ashley N Weeratunga; Sammy Saab
Journal:  Drug Des Devel Ther       Date:  2016-06-29       Impact factor: 4.319

9.  Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study.

Authors:  Patricia Amoros-Reboredo; Dolors Soy; Marta Hernandez-Hernandez; Sabela Lens; Conxita Mestres
Journal:  Int J Environ Res Public Health       Date:  2020-05-26       Impact factor: 3.390

10.  Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.

Authors:  Graham R Foster; Tarik Asselah; Sarah Kopecky-Bromberg; Yang Lei; Armen Asatryan; Roger Trinh; Neddie Zadeikis; Federico J Mensa
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.